Biggest changeJune, 2024 2023 Change Revenue $ 26,000,652 $ 36,441,695 $ (10,441,043 ) Cost of revenue $ 13,176,073 $ 15,421,715 $ (2,245,642 ) Sales and marketing expenses $ 5,989,727 $ 6,067,392 $ (77,665 ) Distribution costs $ 8,611,702 $ 9,465,149 $ (853,447 ) General and administrative expenses $ 6,771,937 $ 6,875,575 $ (103,638 ) Other operating expenses $ 4,848,629 $ 7,146,286 $ (2,297,657 ) Other (expense) $ (3,141,166 ) $ (4,676,160 ) $ 1,534,994 Loss attributable to non-controlling interest $ - $ (559,967 ) $ 559,967 Impairment of intangible assets and goodwill $ 7,869,425 3,746,301 4,123,124 Lease impairment $ 289,969 - 289,969 (Loss) on the sale of assets and businesses $ (456,747 ) (2,212,542 ) 1,755,795 Discontinued operations $ (1,164,184 ) $ (1,370,124 ) $ 2,534,308 Net loss attributable to Upexi, Inc. $ (23,658,438 ) $ (16,930,289 ) $ (6,728,149 ) Revenues decreased by $10,441,043 or 29% for the fiscal year ended June 30, 2024, compared with the fiscal year ended June 30, 2023.
Biggest changeJune, 2025 2024 Change Revenue $ 14,826,336 $ 26,000,652 $ (11,174,316 ) Digital asset revenue $ 985,009 $ - $ 985,009 Product costs $ 4,943,305 $ 13,176,073 $ (8,232,768 ) Distribution costs $ 4,691,964 $ 8,611,702 $ (3,919,738 ) Sales and marketing expenses $ 4,001,094 $ 5,989,727 $ (1,988,633 ) General and administrative expenses $ 11,935,582 $ 6,771,937 $ 5,163,645 Unrealized and realized (gain) loss on digital assets $ (105,474 ) $ - $ (105,474 ) Other operating expenses $ 3,114,620 $ 4,848,629 $ (1,734,009 ) Other (expense) $ (1,184,457 ) $ (3,141,166 ) $ 1,956,709 Impairment of intangible assets and goodwill $ - $ 7,869,425 $ (7,869,425 ) Lease (gain on sale) impairment $ (269,994 ) $ 289,969 $ (559,963 ) (Gain) on the sale of assets and businesses $ - $ (448,882 ) $ 448,882 Income from discontinued operations $ - $ 1,164,184 $ (1,164,184 ) Net loss attributable to Upexi, Inc. $ (13,684,209 ) $ (23,658,438 ) $ 9,974,229 Revenues decreased by $11,174,316, or 43%, for the fiscal year ended June 30, 2025, compared with the fiscal year ended June 30, 2024.
On May 28, 2024, the Company entered into an agreement to sell its Clearwater warehouse for a sale price of $4,300,000. The sale of the building was completed on July 8, 2024 and provided $1,370,978 of working capital. On June 13, 2024, the Company sold all of the issued and outstanding equity of VitaMedica, Inc. to three investors.
On May 28, 2024, the Company entered into an agreement to sell its Clearwater, Florida warehouse for a sale price of $4,300,000. The sale of the building was completed on July 8, 2024 and provided $1,370,978 of working capital. On June 13, 2024, the Company sold all of the issued and outstanding equity of VitaMedica, Inc. to three investors.
On October 17, 2024, Company received written notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Stock Market maintain a minimum bid price of $1.00 per share.
On October 17, 2024, Company received written notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Stock Market maintain a minimum bid price of $1.00 per share.
Results of Operations Year Ended June 30, 2024, as compared to June 30, 2023: The following summary of our results of operations should be read in conjunction with our consolidated financial statements for the years ended June 30, 2024, and 2023, which are included herein.
Results of Operations Year Ended June 30, 2025, as compared to June 30, 2024: The following summary of our results of operations should be read in conjunction with our consolidated financial statements for the years ended June 30, 2025, and 2024, which are included herein.
Reverse Stock Split On September 18, 2024, we filed a Certificate of Change with the Nevada Secretary of State to effect a reverse stock split of our common stock at a rate of 1-for-20 (the "Reverse Stock Split"), which became effective as of October 3, 2024 (the "Effective Date").
Reverse Stock Split On September 18, 2024, we filed a Certificate of Change with the Nevada Secretary of State to effect a reverse stock split of our common stock at a rate of 1-for-20 (the “Reverse Stock Split”), which became effective as of October 3, 2024 (the “Effective Date”).
The increase in the net losses primarily related to the above-mentioned changes.
The decrease in the net losses primarily related to the above-mentioned changes.
One of the minority Interest Buyers is Allan Marshall, the Company’s Chief Executive Officers. The purchase price for the stock was Six Million Dollars ($6,000,000), subject to certain customary post-closing adjustments. The net cash provided from the sale was $2,100,000, reduced liabilities of $1,900,000 and will provide an additional $2,000,000 in cash flow next year.
One of the minority interest buyers is Allan Marshall, the Company’s Chief Executive Officers. The purchase price for the stock was $6,000,000, subject to certain customary post-closing adjustments. The net cash provided from the sale was $2,100,000, reduced liabilities of $1,900,000, a loan for $1,000,000 and a final $1,000,000 payment subject to certain inventory and working capital adjustments.
Key Factors Affecting Operating Results Cyclicality and Seasonality Our business is typically unaffected by seasonality. 23 Table of Contents Operating Segments The Company’s financial reporting is organized into a single segment that includes production, sales and distribution of branded products, following the sale of E-Core, Technology Inc. and its subsidiaries.
Operating Segments The Company’s financial reporting is organized into a single segment that includes production, sales and distribution of branded products, following the sale of E-Core, Technology Inc. and its subsidiaries.
As the per-share par value did not change, we reclassified $19,860 from Common Stock to Additional Paid-in-Capital on the Effective Date.
On the Effective Date, every twenty shares of Common Stock issued and outstanding were automatically combined into one share of Common Stock, without any change in the par value per share. As the per-share par value did not change, we reclassified $19,860 from Common Stock to Additional Paid-in-Capital on the Effective Date.
The income and loss on discontinued operations was as follows: June 30, 2024 June 30, 2023 Interactive Offers $ (187,003 ) $ (1,729,636 ) Infusionz 71,976 (338,418 ) E-Core 1,065,575 1,080,379 VitaMedica 213,636 (382,449 ) $ 1,164,184 $ (1,370,124 ) 25 Table of Contents The Company had a net loss of $21,396,857 compared to a net loss of $16,930,289 in the prior year.
The income and loss on discontinued operations was as follows: June 30, 2025 June 30, 2024 Interactive Offers $ - $ (187,003 ) Infusionz - 71,976 E-Core - 1,065,575 VitaMedica - 213,636 $ - $ 1,164,184 43 Table of Contents The Company had a net loss of approximately $13,684,000 compared to a net loss of approximately $23,658,000 in the prior year.
The Reverse Stock Split was approved by the board of directors in accordance with Nevada law.
The Reverse Stock Split was approved by the board of directors in accordance with Nevada law. The Reverse Stock Split did not have any impact on the par value of common stock.
This loss was offset by a $1,948,538 gain on the sale of VitaMedica and a gain on the sale of Infusionz and CBD related assets, which was recorded as a $2,212,542 loss in the prior year.
In the prior year, the Company recognized a gain on the sale of assets and businesses of approximately $449,000. This gain was from approximately $1,948,538 gain on the sale of VitaMedica, the gain of approximately $238,000 on the sale of Infusionz and CBD related assets, which recorded an approximate loss of $2,186,000 in the prior year.
Other operating expenses decreased by $2,297,657 or 32% compared with the same period last year. These expenses are primarily non-cash expense for amortization of stock compensation, amortization of acquired intangible assets and depreciation. The decrease in the amortization of stock compensation was $2,494,695 as older grants are fully amortized and there have only been limited grants in the past year.
Other operating expenses decreased by approximately $1,734,000, or 36%, compared with the same period last year. These expenses are primarily non-cash expense for amortization of stock compensation, amortization of acquired intangible assets and depreciation. The decrease in the amortization of acquired intangible assets was approximately $2,334,000 as approximately $7,869,000 was impaired in the prior year.
Liquidity and Capital Resources Working Capital As of June 30, 2024 As of June 30, 2023 Current assets $ 11,419,918 $ 30,012,984 Current liabilities $ 12,655,152 $ 22,391,587 Working capital $ (1,235,234 ) $ 7,621,397 Cash Flows Years Ended June 30, 2024 2023 Cash flows (used in) operating activities – continuing operations $ (4,894,751 ) $ (7,421,529 ) Cash flows provided by (used in) investing activities – continuing operations 831,112 (23,271 ) Cash flows (used in) provided by financing activities – continuing operations (353,789 ) 6,032,901 Cash flows provided by operating activities – discontinued operations 4,793,374 7,624,206 Cash flows used by investing activities – discontinued operations (4,206,823 ) (2,551,587 ) Cash flows used by financing activities – discontinued operations - (6,318,234 ) Net decrease in cash during the period $ (3,830,877 ) $ (2,657,514 ) On June 30, 2024, the Company had cash of $661,415 or a decrease of $3,830,877 from June 30, 2023.
Liquidity, Capital Resources and Cash Requirements Working Capital As of June 30, 2025 As of June 30, 2024 Current assets $ 56,778,043 $ 11,419,918 Current liabilities $ 32,563,906 $ 12,655,152 Working capital $ 24,214,137 $ (1,235,234 ) Cash Flows Years Ended June 30, 2025 2024 Cash flows (used in) operating activities – continuing operations $ (8,423,042 ) $ (4,894,751 ) Cash flows (used in) provided by investing activities – continuing operations (99,293,083 ) 831,112 Cash flows provided by (used in) financing activities – continuing operations 110,029,860 (353,789 ) Cash flows provided by operating activities – discontinued operations - 4,793,374 Cash flows used by investing activities – discontinued operations - (4,206,823 ) Cash flows used by financing activities – discontinued operations - - Net increase (decrease) in cash during the period $ 2,313,735 $ (3,830,877 ) On June 30, 2025, the Company had cash of $2,975,150, or an increase of approximately $2,314,000, from June 30, 2024.
The Company recognized an impairment $289,969 on the Delray Beach warehouse during 2024 as part of closing the warehouse and the Company exiting the recommerce business. No such items for 2023. The Company recognized a valuation allowance on its deferred tax asset of $6,100,000 during the year ended June 30, 2024.
The Company recognized an impairment $289,969 on the Delray Beach warehouse during the year ended June 30, 2024 as part of closing the warehouse and the Company exiting the recommerce business. This liability was settled in January of 2025 and resulted in a gain on the lease impairment of approximately $270,000.
Management intends to finance operating costs over the next twelve months from the date of the issuance of these consolidated financial statements with existing cash on hand, cash flow from operations, proceeds from the sale of VitaMedica not yet received and additional short term debt financings, if necessary. 27 Table of Contents We estimate that we will have sufficient working capital to fund our operations over the twelve months following the date of the issuance of these condensed consolidated financial statements and meet all our debt obligations.
We estimate that we will have sufficient working capital to fund our operations over the twelve months following the date of the issuance of these consolidated financial statements and meet all of our debt obligations.
The initial term is five years. The estimated cost of this facility is a reduction of overall facility costs of approximately $240,000 in rent and approximately $138,000 per year in utilities, repairs and maintenance. Management also expects to have additional savings in labor and administrative costs, which is expected to add additional cash flow for fiscal year 2025.
The lease is for approximately 10,000 square feet of warehouse and office space, located in Odessa, Florida for $20,060 per month on a triple net basis. The initial term is five years. The estimated cost of this facility is a reduction of overall facility costs of approximately $240,000 in rent and approximately $138,000 per year in utilities, repairs and maintenance.
The $2,511,587 used in discontinued investing activities was $500,000 for the acquisition of VitaMedica and $2,051,587, net of cash acquired, for the acquisition of E-core. 26 Table of Contents Net cash flows used in financing activities for the year ended June 30, 2024 was $353,789 compared to $285,333 used during the year ended June 30, 2023.
This was offset by the collection of the purchase price in the sale of E-core and the proceeds from the sale of the building. Net cash flows provided by financing activities for the year ended June 30, 2025 was approximately $110,030,000 compared to approximately $354,000 used during the year ended June 30, 2024.
An impairment of goodwill in the amount of $2,889,158 was recorded at June 30, 2023 eliminating all of the goodwill related to Interactive Offers. 28 Table of Contents Revenue Recognition - In accordance with ASC No. 606, Revenue from Contracts with Customers, the Company recognizes revenue when we satisfy performance obligations as evidenced by the transfer of control of our products or services to customers.
Management believes the areas described below require significant judgment in the application of accounting policy or in making estimates and assumptions that are inherently uncertain and that may change in subsequent periods. 46 Table of Contents For further information, see Note 2 to the Consolidated Financial Statements, “Significant Accounting Policies.” Revenue Recognition - In accordance with ASC No. 606, Revenue from Contracts with Customers, the Company recognizes revenue when we satisfy performance obligations as evidenced by the transfer of control of our products or services to customers.